Maria Rodriguez, M.D., M.P.H. and a team of OHSU researchers adapt a mini-sponge prototype to control postpartum hemorrhage within 1 minute of placement.
Comment from Mark Slifka is included in an article about the safety of AstraZeneca’s COVID-19 clinical trial following the untimely and unrelated death of a study participant.
Ajit Jetmalani, M.D., discusses the importance of community-based social supports, including those offered by in-person school, for children who experience trauma due to Oregon wildfires, COVID-19.
In an article describing what patients should consider before seeking experimental coronavirus treatments, Annette Totten, M.D., says: “The challenge is the evidence is not good because everything with COVID is new. I think it’s hard to cut through all the noise.”
In an editorial about unintended consequences of closing businesses to tame the pandemic, Robert Duehmig notes some health care works were laid off after non-essential procedures were temporarily halted. “Thanks to federal dollars, everybody’s still here. But some providers are just hanging on,” he says.
Ymir Genomics LLC and the OHSU Knight Cancer Institute announce a licensing agreement and filed patent application to protect and promote newly-discovered high value urinary biomarkers for detecting cirrhosis and/or hepatocellular carcinoma (HCC) in at-risk patient populations. Christina Binder, M.D., Ph.D., says: “There is a real need for non-invasive, widely available biomarkers for cirrhosis and HCC. We believe this collaboration will further the work on early detection of these diseases."